Skeletal muscle hypertrophy and anti‐atrophy effects of clenbuterol are mediated by the β2‐adrenergic receptor

Muscle and Nerve - Tập 25 Số 5 - Trang 729-734 - 2002
Richard T. Hinkle1, Karen M. Hodge1, David B. Cody1, Russell J. Sheldon1, Brian K. Kobilka2, Robert J. Isfort1
1Research Division, Procter & Gamble Pharmaceuticals, 8700 Mason‐Montgomery Road, Mason, Ohio 45040‐9317, USA
2Howard Hughes Medical Institute, Stanford University, Stanford, California, USA

Tóm tắt

Abstract

Analyses were performed to evaluate the roles of the β1‐ and β2‐adrenergic receptors in the skeletal muscle hypertrophy and anti‐atrophy response to the β‐adrenergic agonist, clenbuterol. Treatment of wild‐type mice with clenbuterol resulted in statistically significant hypertrophy of the innervated tibialis anterior and medial gastrocnemius muscles and inhibition of denervation‐induced atrophy of these muscles. Treatment of β1‐adenergic receptor knockout mice with clenbuterol also resulted in statistically significant hypertrophy of the innervated tibialis anterior and medial gastrocnemius muscles and inhibition of denervation‐induced atrophy of these muscles. In contrast, in β2‐adrenergic receptor knockout mice and in mice lacking both the β1‐ and β2‐adrenergic receptors, clenbuterol treatment did not result in hypertrophy of the innervated tibialis anterior and medial gastrocnemius muscles, nor did it inhibit denervation‐induced atrophy in these muscles. Together these data demonstrate that the β2‐adrenergic receptor is responsible for both the skeletal muscle hypertrophy and anti‐atrophy effects of the β‐adrenergic agonist clenbuterol. © 2002 Wiley Periodicals, Inc. Muscle Nerve 25: 000–000, 2002

Từ khóa


Tài liệu tham khảo

10.2527/jas1987.6561514x

10.2527/jas1989.6792255x

10.1016/0300-9084(93)90037-S

10.1249/00005768-199511000-00002

10.1016/0006-2952(88)90186-4

10.1007/BF01119805

10.1074/jbc.274.24.16694

10.1007/BF01120827

Evans BA, 1996, Expression of β3‐adrenoceptor mRNA in rat tissues, Br J Pharmacol, 1, 7:210

10.1016/S0165-6147(99)01347-4

10.1016/S0165-6147(00)01562-5

10.1212/WNL.50.5.1402

10.1079/BJN19900140

10.1042/cs0840651

10.1111/j.1476-5381.1989.tb11889.x

10.1007/BF01116510

10.1016/0014-2999(91)90179-T

10.1016/0742-8413(88)90234-4

10.1074/jbc.274.24.16701

10.1073/pnas.93.14.7375

10.1152/ajpheart.1998.274.4.H1184

10.1016/S0003-9993(95)80043-3

10.1111/j.1476-5381.1994.tb14818.x

10.1152/ajpendo.1995.268.1.E159